[go: up one dir, main page]

WO1991008749A1 - Nouveau procede permettant d'obtenir des proteines en partant d'un extrait de proteines non collagenes provenant de tissu osseux et utilisation de ce procede pour la preparation d'une nouvelle proteine inhibant la proliferation des osteoblastes - Google Patents

Nouveau procede permettant d'obtenir des proteines en partant d'un extrait de proteines non collagenes provenant de tissu osseux et utilisation de ce procede pour la preparation d'une nouvelle proteine inhibant la proliferation des osteoblastes Download PDF

Info

Publication number
WO1991008749A1
WO1991008749A1 PCT/EP1990/002295 EP9002295W WO9108749A1 WO 1991008749 A1 WO1991008749 A1 WO 1991008749A1 EP 9002295 W EP9002295 W EP 9002295W WO 9108749 A1 WO9108749 A1 WO 9108749A1
Authority
WO
WIPO (PCT)
Prior art keywords
tyr
pro
gly
protein
thr
Prior art date
Application number
PCT/EP1990/002295
Other languages
English (en)
Inventor
Patrick Mahy
Hugo Van Heuverswyn
Original Assignee
N.V. Innogenetics S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N.V. Innogenetics S.A. filed Critical N.V. Innogenetics S.A.
Publication of WO1991008749A1 publication Critical patent/WO1991008749A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Definitions

  • the subject of the invention is a novel procedure for obtaining and purifying proteins starting from an extract of non-collagenous proteins from bone matrix.
  • Another subject of the invention is a device for the implementation of the procedure of the invention.
  • Another subject of the invention is an inhibitory protein of the proliferation of osteoblasts likely to be obtained by the above-mentioned procedure.
  • compositions containing as active substance the above-mentioned protein intended in particular for the treatment of Paget's disease, osteosarcomas.
  • Another subject of the invention is the utilization of the protein for the diagnosis of a disease likely to be correlated with a concentration located outside the range of values usually attributed to a healthy individual.
  • Bone is an extremely specialized tissue with unique mechanical properties which are derived from its special matrix structure. Although it is composed above all of mineral substances, the small amount of protein which it contains is, however, indispensable for its growth, its maintenance including its permanent remodeling and its repair.
  • collagen the activity of which is to ensure the resistance of bone to tension, including proteoglycans, non-collagenous proteins, lipids and the acidic proteins associated with the mineral part constituted of hydroxyapatite crystals. cells. Osteogenesis is conducted by the osteoblasts, the cells forming bone. The tissue remodeling which bone undergoes apparently results from the interaction between the cells resorbing bone, i.e. the osteo-
  • Urist, Huo, Brownell et al. have demonstrated the presence of non-collagenous proteins associated with the bone matrix, have isolated them by acting on demineralized bone by means of a
  • this protein was isolated from a non-collagenous extract (derived from demi r li ed bone) insoluble in Triton X-100 and in water, to electrophoresis on
  • the slices of the gel were extracted with 6M urea in order to isolate More precisely, in the article previously cited, it is pointed out that this protein was isolated from a non-collagenous extract (derived from demineralized bone) insoluble in Triton X-100 and in water, the extract of which was subjected to electrophoresis on polyacrylamide gel in the presence of sodium dodecylsulfate (SDS-PAGE), which gives bands, each of which corresponds to the visualization of an individual protein; the acrylamide gel was then cut into slices in order to separate the individual bands.
  • SDS-PAGE sodium dodecylsulfate
  • a preparative electrophoresis on gel was then carried out: the slices of the gel were extracted with 6M urea in order to isolate the individual proteins from their support. They were subjected again to an electrophoresis on slab gels in order to confirm their molecular weight and their purity (absence of contaminants). This has made it possible in particular to separate a protein of molecular weight of 18, 500 daltons which has been designated as "BMP".
  • the authors provide another method for obtaining the protein.
  • This procedure is the following: the above-mentioned protein has also been isolated from a non-collagenous extract insoluble in Triton X-100 and in water, derived from demineralized bone, the extract of which was subjected to chromatography on a hydroxyapatite column in order to recover the fraction containing three proteins of molecular weight ranging from 17,000 to 18,000 daltons separated from the proteins of molecular weight were then separated from the gel slices by electroelution (Development and Diseases of Cartillage and Bone Matrix, p. 149-176, 1987, Alan R. Liss, Inc.; M.R. Urist et al.).
  • Urist et al. have also described osteogenesis. as a classical biological system containing osteo-inducing substances (demonstrated) (cf. above) and inhibitory substances (not characterized) which can act on the mitoses of osteoblasts, for example, or on the differentiation of osteo-progenitor cells (1).
  • osteoblast cells ROS 17/2.8
  • osteosarcoma linerby40%to70% This protein shows a complete sequence homology with osteonectin (2)
  • the subject of the present invention is to provide a novel procedure making it possible to separate and purify individual proteins in a satisfactory state of homogeneity and biologically active, starting from an extract of non-collagenous proteins of bone matrix.
  • Another subject of the present invention is a procedure for renaturation and/or reactivation of proteins obtained starting from an extract of noncollagenous proteins of bone matrix.
  • Another subject of the invention is a novel preparative chromatography column likely to be implemented in the procedure of the invention.
  • Another subject of the invention is a novel protein likely to be obtained by the procedure of the invention and possessing interesting biological properties of inhibition of the proliferation of osteoblasts.
  • compositions containing as active substance the protein of the invention are also subject of the invention.
  • Another subject of the invention is a novel diagnostic procedure, involving the protein of the invention and/or antibodies, in particular polyclonal antibodies and especially monoclonal antibodies directed against this protein.
  • the extract of non-collagenous protein dissolved beforehand in a solvent, is subjected to a preparative chromatography in the liquid phase on a gel column with the aid of an elution buffer and an electric field under conditions such that the desired protein is eluted and is found, during or at the end of the chromatography, to be present in solution in the elution buffer, alone and free of contaminants, in at least one of the fractions recovered at the exit of the column, - the fraction containing the sought protein in solution in the elution buffer is recovered, the elution buffer is removed and the desired protein is recovered and, if necessary, is subjected to a renaturation step and/or a reactivation step.
  • An advantageous procedure of the invention of a protein purified to a satisfactory homogeneous state, starting from an extract of non-collagenous proteins of bone matrix, is characterized in that it comprises the following steps:
  • the fraction containing the desired protein in solution in the elution buffer is recovered, the elution buffer is removed and the desired protein is recovered, and, if necessary, is subjected to a renaturation step and/or a reactivation step.
  • the procedure of the invention makes it possible to separate proteins starting from a set of non- collagenous proteins of bone matrix and to separate them individually in purified form and biologically active and in the same way makes it possible to obtain a specific protein in a purified form and biologically active.
  • the procedure of the invention presents the advantage of limiting the number of fractionations, hence, consequently, of limiting the loss of the product.
  • a protein in a satisfactory state of homogeneity shows constant and reproducible characteristics within standard experimental deviations with respect to parameters which are the following: amino acid analysis, spectrum of bands in standard electrophoresis on polyacrylamide gel (PAGE) or another chromatographic technique, molecular weight, isoelectric point, biological properties and other parameters.
  • PAGE polyacrylamide gel
  • the expression "purified to a satisfactory homogeneous state” means in particular that the protein is free of contaminants which, if they were present, would modify the biological properties of the protein.
  • extract of non-collagenous proteins of a bone matrix designates a set, for example, an aggregate of non-collagenous proteins extracted from a bony tissue, advantageously demineralized.
  • demineralized bony tissue mention may be made of bones, dentine or osteosarcomas.
  • the extract of non-collagenous proteins of a bone matrix may be obtained by treating a bone in the following manner:
  • long bones diaphysis of long bones
  • a mammal for example bovine tibia
  • diaphyses derived from femurs or tibias of rats it is possible to start from long bones (diaphysis of long bones) from a mammal (for example bovine tibia) or from the diaphyses derived from femurs or tibias of rats.
  • a practical method of treatment for demineralization of a bone is the following: the periosteal layer surrounding the bone (the bone is preferably taken from a young mammal) is taken from a young mammal.
  • the bones taken immediately after slaughter of the animal are cleaned.
  • the soft tissues adhering to the bone are resected, for example manually (with the aid of a scalpel).
  • the bone marrow is removed by successive washings with cold water.
  • the bone is then cut into small pieces of about 2 cm, soaked in liquid nitrogen then powdered in fine particles (I 500 ⁇ m) with the aid of a grinder (Wiley).
  • the homogenized particles are washed with a saline solution or a buffer, such as Tris-HCl buffer (pH 7.0) or 0.15 M NaCl and water, then with an ethanol/ether solution or a chloroform/methanol solution in a volume/volume ratio equal to 1.
  • a saline solution or a buffer such as Tris-HCl buffer (pH 7.0) or 0.15 M NaCl and water
  • an ethanol/ether solution or a chloroform/methanol solution in a volume/volume ratio equal to 1.
  • the washed homogenized particles are then dried in a vacuum or in air: this bone powder may be stored at -80°C for prolonged periods of time.
  • the bone powder is sieved in order to obtain particles having a range of size of about 75 to 500 ⁇ in diameter.
  • the demineralization i.e.
  • the demineralized bone powder is then washed with deionised distilled water until the pH approaches neutrality.
  • the demineralized bone powder may be stored at very low temperatures, for example from -20 to -80°C.
  • the demineralization of the bone powder may also be carried out by using other known standard procedures, for example by utilizing a chelating agent such as ethylenediaminetetraacetic acid.
  • a chelating agent such as ethylenediaminetetraacetic acid.
  • the powder, rinsed with water may be tested for its mineral content, for example by the method of Von Kossa, see J. Von Kossa, Ziegler ' S Beitr. 29 , 163 (1901) .
  • the Von Kossa spot is negative, the treated bone powder is sufficiently demineralized to be suitable for the extraction of the proteins.
  • the extract of non-collagenous proteins may be extracted from the demineralized bone tissue according to the method of Urist (1).
  • the non-collagenous proteins are extracted by dissolution of the bone powder in a solution of 4 M GuHCl/0.5 M CaCl 2 or 6 M urea/0.5 M CaCl 2 and 1.0 mM of N-ethylmaleimide (NEM) 0.1 mM of benzamidine-HCl per liter, and are stirred at room temperature for 24 h, which gives rise to a suspension,
  • NEM N-ethylmaleimide
  • the above-mentioned suspension is filtered through a Whatman filterpaper, the filtered volume obtained is transferred to an ultrafiltration device with 10 K hollow fibres (Amicon), which makes it possible to obtain a final volume to be dialysed less than or equal to 10% of the filtered volume and makes possible an easier and more efficacious dialysis.
  • the proteins, defatted and soluble in 4M GuHCl are dissolved in 100 volumes of GuHCl; the insoluble material is centrifuged; the supernatant is dialysed against one volume of cold water which decreases the GuHCl concentration from 4 to 1.5 M; this separates the insoluble 24 K protein from the proteins soluble in 1.5 M GuHCl, by differential precipitation; the solution is centrifuged at 9000 rpm for 30 min. at 4oC;
  • the precipitate is washed 3 times with cold water and lyophilized, then the soluble proteins are dialysed in 1.5 M GuHCl in order to produce a precipitate; the proteins insoluble in water and soluble in 1.5 M GuHCl are centrifuged and washed 3 times with cold water;
  • the moist proteins are redissolved in 1 1 of 4 M GuHCl/0.5 M CaCl 2 and dialysed against an equal volume of 4 M GuHCl containing 0.10 M of Trizma-HCl, pH 7.2 and 0.2% or Triton X-100 (0.2 g per 100 ml) (ref. 1); the protein of 34 K is dissolved;
  • Triton X-100 the precipitate insoluble in Triton X-100 is centrifuged; an extract of non-collagenous proteins is obtained free from proteins of 6 K, 24 K and 34 K; it is dialysed and extracted against deionized water at
  • the precipitate obtained by dialysis against water at 4oC is then taken up again and redissolved in 6 M urea and is purified by ultrafiltration; when it is dialysed again against water, most of the content of the dialysis membrane does not precipitate and the soluble portion is lyophilized and recovered.
  • Gu represents guanidine.
  • the starting extract of non-collagenous proteins of the bone matrix used as starting material in the procedure of the invention is advantageously insoluble in water, and is either insoluble in Triton X-100, or is soluble in Triton X-100.
  • the extract of non-collagenous proteins of bone matrix is advantageously insoluble in water and insoluble in Triton X-100.
  • the current is advantageously applied between an upper reservoir (situated in the neighbourhood of the top of the column and which feeds the column with elution buffer) and a lower reservoir (situated at the base of the column) in which the column rests and in which the elution buffer is found after passage through the gel.
  • the two parameters to take into account are the density of the gel (i.e. the size of the meshes) and the intensity of the current: if the gel is too dense compared with the size of the proteins to be eluted, it is necessary to increase the current on account of the retention caused by the density of the gel, which leads to too high a temperature, likely to denature the proteins.
  • the intensity of the current should not exceed about 70 mA, and the voltage (U) should not exceed about 150 V.
  • the gel may be selected from among acrylamide- bisacrylamide gel and may be composed of different concentrations of acrylamide, for example about 20% - about 12% - about 3%, or formed of a linear or non linear gradient of about 25% to about 3%, and advantageously from about 20% to about 3%.
  • the gel is a polyacrylamide gel, the density of which is selected as a function of the size of the desired protein.
  • the density of the acrylamide gel used is less than or equal to 10%;
  • the density of the acrylamide gel used is higher than or equal to about 10%;
  • the density of the acrylamide gel used is higher than or equal to about 15%;
  • the density of the acrylamide gel used is higher than or equal to about 20%.
  • the polyacrylamide gel which fills the column may advantageously be constituted by an initial layer of gel of low density (about 3%) (concentration gel) and a second layer of gel of higher density (about 12% to about 17%) (resolution gel).
  • the part of the gel corresponding to the resolution may itself be constituted of two different densities, for example a layer of about 12% to about 15% , and a second layer of about 15% to about 17%.
  • an advantageous solution buffer is constituted by:
  • the proteins contained in the starting extract are separated and each individual protein is found alone in at least one tube of the collector, and may be found alone in several tubes.
  • the set of tubes is such that in principle the number of tubes in which a specific protein is found depends on the rate of elution.
  • the elution buffer of the preparative chromatography is removed in order to recover the desired protein.
  • the step for the removal of the elution buffer may be carried out under conditions such that there is at the same time renaturation and/or reactivation of the sought protein, in particular in the case in which the elution buffer contains elements likely to denature the proteins, such as sodium dodecylsulfate.
  • the precipitate or advantageously the content of the dialysis membrane i.e. the precipitate and the supernatant obtained at the end of that one of the two dialyses which constitutes the first step, is solubilized in order to be dialysed.
  • the precipitate or advantageously the whole of the content of the dialysis membrane i.e. the precipitate and the supernatant
  • the whole of the content of the dialysis membrane is recovered in order not to lose the proteins which might have passed into the supernatant, and advantageously the whole of the content of the dialysis membrane is then lyophilized, which makes it possible to store the lyophilizate obtained
  • the redissolution of the lyophilizate is then carried out, in particular with the aid of GuHCl of molarity of about 4 M to about 8 M, in particular 6 M or of urea of about 4 M to about 8 M, in particular 6 M,
  • the volume of solvent depends on the amount of material to be dissolved and the capacity of this material to be soluble in the GuHCl solution.
  • SDS SDS
  • the elution buffer it is advantageous, on the one hand, to remove it to the extent that it denatures the proteins, i.e. causes them to loose their biological properties, and, on the other hand, to the extent that it is toxic for the cells, both in vivo and in vitro.
  • the preparative chromatography of the invention is advantageously carried out with a system such that the elution buffer is added continuously in order that there is no limitation of the elution by the volume of the elution buffer. It is possible to make provision for a continuous feeding device or indeed provide an upper reservoir situated above the column, which reservoir is placed in contact with a sufficient quantity of elution buffer, which makes it possible to replenish the upper reservoir as the elution solvent is used up.
  • the preparative chromatography makes it possible to utilize considerable quantities of starting extract of non-collagenous proteins of bone matrix since it is not limited by the elution volume.
  • the extract used may vary from 20 to 100 mg, this being a function of the percentage which the desired protein represents in relation to the extract.
  • the preparative chromatography step is preceded by a preliminary step of fractionation of all of the non-collagenous proteins, making it possible to obtain a fraction enriched in the desired protein, which enriched fraction is then subjected to the preparative chromatography step.
  • the preliminary step may be constituted by any separation which makes it possible to obtain a fraction enriched in the sought protein.
  • a fraction enriched in the sought protein For example, it is possible to have recourse to a Sephacryl filtration, to a DEAE or to a chromatography on hydroxyapatite.
  • the buffer is removed, in particular when this latter is different from the solubilization buffer and from the elution buffer used in the preparative chromatography, and the fraction enriched in the desired protein is redissolved in a solubilization buffer compatible with the elution buffer of the preparative chromatography, the solubilization buffer containing in particular urea, and being preferably constituted by a mixture: urea, Tris-HCl, and SDS.
  • the preliminary step is constituted by a chromatography on hydroxyapatite, designated hereafter by HAP chromatography.
  • HAP chromatography is performed as indicated for example in the following documents: Proc. Natl. Acad. Sci. USA, vol. 81, pp. 371-375, January 1984, M.R. Urist et al.; Development and Diseases of Cartillage and Bone Matrix, p. 149-176, 1987, Alan R. Liss, Inc.
  • the buffer 0 the composition of which is the following:
  • the stock phosphate solution is obtained in the following manner:
  • the elution buffer advantageously used in HAP chromatography is the same as that used to solubilize the extract of non-collagenous proteins.
  • the HAP chromatography progresses such that it is possible to collect fractions (each usually containing several proteins), which fractions are eluted as a function of the affinity of the proteins which they exhibit towards hydroxyapatite.
  • the HAP chromatography is advantageously done at a concentration of 10 mM to 500 mM of phosphate buffer, and advantageously of 10 mM to 250 mM of phosphate buffer.
  • the fraction containing the desired protein is determined, for example, by SDS-PAGE electrophoresis.
  • the lyophilization of the precipitate obtained after the dialysis step it is also possible to concentrate the precipitate obtained after the dialysis by centrifugation, and after the concentration step, it is possible to pass over a membrane of the Amicon type, for example, and redissolve the concentrate obtained in the solubilization buffer of the preparative chromatography to the extent to which the volume of the solubilization buffer does not lead to too large a volume which does not exceed the capacity of the preparative column.
  • the resolubilization of the lyophilized precipitate obtained after the HAP chromatography may take place in a solubilization buffer containing per 100 ml:
  • urea about 12 g, adjusted to a pH of 6.8 (concentrated HCl).
  • the procedure of the invention comprising the preliminary step of fractionation makes it possible to enrich the starting extract in a ratio such that by starting from about 4 g of starting extract, a fraction enriched in protein is obtained containing about 215 mg of sought protein, which makes it possible to obtain about 0.350 mg of the sought protein after the preparative chromatography. If one starts with the same amount of starting extract, treated directly in preparative chromatography for about 100 mg of starting extract, about 0.250 mg of sought protein is obtained after the preparative chromatography.
  • the preliminary step of fractionation makes it possible to improve the yield of the quantity of desired protein by a factor of about 20 fold, and the sum of the preliminary fractionation step and the preparative column chromatography make it possible to improve the yield of the quantity of desired protein by a factor of about 400 fold.
  • the preparative chromatography thus takes place on a fraction enriched in the desired protein and it occurs as was described with regard to the preparative chromatography carried out on an extract of non-collagenous protein of bone matrix.
  • the HAP chromatography makes it possible to treat about 10 mg of proteins per g of HAP. In the case of large quantities of proteins to be purified, this ratio may be increased to about 20 mg of proteins/g of HAP.
  • a particularly advantageous procedure for obtaining a protein of the invention is characterized in that - a demineralized, ground and defatted extract of non- collagenous proteins of bone matrix is subjected to a chromatography on hydroxyapatite, the extract of the non-collagenous proteins having been solubilized beforehand, preferably in the same buffer as the elution buffer of the HAP chromatography, in particular the buffer 0,
  • the elution buffer of the HAP chromatography is removed, in particular by dialysis against distilled water and the precipitate obtained is recovered, possibly lyophilized, containing a fraction enriched in the desired protein,
  • the fraction enriched in the desired protein is subjected to a preparative chromatography after having been dissolved in a solvent advantageously containing urea, the acrylamide gel of the preparative column having a density such that it makes possible the elution of the desired protein with the aid of an elution buffer advantageously containing SDS, and with the aid of an electric field, and the conditions of chromatography being such that the desired protein is found alone in solution in the elution buffer, and free of contaminants in at least one of the tubes of the collector corresponding to the fractions collected in parallel to the chromatogram,
  • the protein is recovered, if necessary reactivated and/or renaturated by removing the elution buffer of the preparative chromatography, in particular
  • the precipitate, and possibly the supernatant, obtained containing the desired protein may be lyophilized, the SDS being completely removed as well as the above- mentioned solubilization agent after this second dialysis,
  • the content of the dialysis membrane i.e. the precipitate and the supernatant, is recovered in order to avoid losing the desired protein.
  • the two dialyses when, after the preparative chromatography step, the two dialyses are carried out, separated by a dissolution and when the elution buffer of the preparative chromatography is a mixture of SDS, glycine and Tris-HCl, and the solubilization agent between the two dialyses is urea or GuHCl, the purpose of the initial dialysis is to partially remove SDS as well as Tris-HCl and glycine, whereas the purpose of the second dialysis is to remove the SDS as well as the urea or GuHCl completely.
  • the advantage of the procedure of the invention is to be able to obtain a protein of molecular weight of about 27 kD, possessing inhibitory properties towards the proliferation of osteoblasts, this protein being obtained by the procedure comprising the following steps:
  • the fraction eluted at a concentration of 10 mM of phosphate buffer is recovered in solution in the elution buffer and containing a fraction enriched in the sought protein
  • the buffer is removed in particular by dialysis against distilled water in order to obtain a precipitate, possibly lyophilized,
  • this solubilized fraction enriched in the desired protein is subjected to a preparative chromatography with the aid of an elution buffer, the function of which is also to charge the proteins to be eluted with negative charges, which buffer contains in particular SDS, and the protein of molecular weight of about 27 kD is collected in solution in the elution buffer,
  • the above-mentioned protein in solution in the elution buffer of the preparative chromatography is subjected to two dialyses: namely, a first dialysis against a mixture of PBS, BSA and Tween-20, and a second dialysis against distilled water, these two dialyses being carried out in any order, and these two dialysis steps being separated by the recovery of the content of the dialysis membrane, or of the precipitate resulting from the dialysis, which content or precipitate is completely solubilized in urea or GuHCl,
  • Another subject of the invention is a device for preparative chromatography in the liquid phase.
  • This device consists of
  • this reservoir fitted with a negative electrode being intended to receive the elution liquid, and being fed almost continuously in order that the level of the elution liquid in the reservoir is practically constant
  • first disk a porous disk, advantageously plastic (called here “first disk") which maintains the gel in the column, and a ring situated under the above-mentioned disk which determines the volume of the elution chamber,
  • a second disk preferably of plastic, situated under the intermediate membrane, this second disk being itself placed on a third disk, in particular of plexiglass, which makes possible the passage of the current and which seals the base of the column by means of fastenings such as screws situated on the perimeter of the third disk and defining a ring
  • the second and third disks contiguous to the intermediate membrane and the intermediate membrane being advantageously pierced at their center by a small orifice allowing the passage of a capillary connecting the elution chamber to the fraction collector, in particular via a pump, - a lower reservoir in which the base of the column with the elution chamber is immersed, this reservoir containing a volume at least equal to that of the upper reservoir and advantageously having dimensions identical with those of the upper reservoir, this lower reservoir containing a positive electrode as well as the same buffer as that of the upper reservoir, the volumes of the reservoirs being maintained constant by the flow from the upper reservoir into the lower reservoir which is emptied as a function of the speed of rotation
  • this device consists of a column filled with acrylamide-bisacrylamide gel, the upper outlet of the column being connected to an upper reservoir (for example by the intermediary of a joint situated under the reservoir), intended to receive the elution liquid.
  • This reservoir fitted with the negative electrode for example platinum wire
  • This reservoir fitted with the negative electrode is itself replenished almost continuously in order that the level of the elution liquid in the reservoir is practically constant.
  • the gel is maintained in the column by a porous disk, advantageously plastic (called here “first disk”) and a collar situated under the above-mentioned disk, determines the volume of the elution chamber.
  • a porous disk advantageously plastic (called here “first disk”) and a collar situated under the above-mentioned disk, determines the volume of the elution chamber.
  • a membrane for example Amicon 10 kD (called here “intermediate membrane”) (which allows proteins of molecular weight less than 10 kD to pass) and which retains in the elution chamber the proteins of molecular weight equal to or greater than 10 kD.
  • the first disk and the collar determining the volume of the elution chamber are situated at the interior of a collar of larger diameter than the diameter of the elution chamber, which collar accommodates all of the upper part of the device, including the column, the lower end of which fits into the said collar.
  • This device may advantageously include a second disk, situated under the intermediate membrane.
  • This porous disk preferably of plastic, provides a stability to the system.
  • the second disk is itself placed on a third disk, in particular of plexiglass, which makes possible the passage of the current and which seals the base of the column by means of fastenings such as screws, situated on the perimeter of the third disk and defining a ring.
  • the second and third disks contiguous to the membrane and the membrane are advantageously pierced in their center by a small orifice allowing the passage of a fine capillary connecting the elution chamber to the fraction collector via a pump.
  • the capillary opens into the upper part of the elution chamber and stops under the first disk which it does not cross.
  • the capillary discharges in the neighbourhood of the center of the first disk has the advantage of a direct and effective recovery of the proteins.
  • the proteins after the passage through the gel, are found at the base of the gel, but in view of the properties of the system, the proteins have a tendency to be found at the center of the acrylamide in relation to the transverse plane of the column, following upon the suction generated by the pump.
  • the base of the column with the elution chamber is immersed in a lower reservoir which can contain a volume at least equal to that of the upper reservoir and having advantageously dimensions identical to those of the upper reservoir, this lower reservoir containing a positive electrode (for example, platinum wire) as well as the same buffer as that of the upper reservoir.
  • a positive electrode for example, platinum wire
  • the volumes of the reservoirs are maintained constant by the flow from the upper reservoir into the lower reservoir which is emptied as a function of the speed of rotation of the pump (for example with 4 channels) which pumps the proteins in the buffer of the elution chamber towards the collector while filling the upper reservoir at the same speed.
  • the whole may form a closed circuit if the buffer is recycled or if it is a matter of a fresh buffer supplied to the upper reservoir at the same speed as it is pumped into the lower reservoir.
  • the dimensions of the device of the invention may be the following:
  • the upper reservoir may accommodate a volume of about
  • the column has a height of about 18 cm and a diameter of about 4 cm
  • the elution chamber has a volume of about 6 ml, that is, a height of about 0.5 cm and a diameter of about 2 cm,
  • the collar of larger diameter than that of the elution chamber has a diameter of about 4 cm to about 5 cm
  • the capillary has an internal diameter of about 10 ⁇ to about 20 ⁇
  • the lower reservoir contains a volume at least equal to that of the upper reservoir.
  • Another subject of the invention is a peptide, polypeptide or protein comprising at least one of the following peptide sequences: S1 :
  • Another subject of the invention is a peptide, polypeptide or protein, comprising in its peptide sequence one of the sequences defined below, or constituted by one of the sequences defined below:
  • the subject of the invention is a peptide, polypeptide or protein inhibitory to the proliferation of osteoblasts comprising at least one of the peptide sequences S1, S2, S3, S1S2, S1S3, S2S1, S3S1, S2S3, S3S2, S1S2S3, S1S3S2, S2S1S3, S2S3S1, S3S1S2 or S3S2S1, defined above, exhibiting a molecular weight of about 27 kD (27,000 daltons), determined by SDS-PAGE electrophoresis (one-dimensional or two- dimensional).
  • the subject of the invention is a peptide, polypeptide or protein (inhibitory) of the proliferation of osteoblasts comprising at least one of the peptide sequences S1, S2, S3, S1S2, S1S3, S2S1, S3S1, S2S3, S3S2, S1S2S3, S1S3S2, S2S1S3, S2S3S1, S3S1S2 or S3S2S1, defined above, exhibiting a molecular weight of about 27 kD, determined by one-dimensional SDS-PAGE electrophoresis and an isoelectric point of about 4.0 to about 5.5, measured by two-dimensional SDS-PAGE electrophoresis according to the technique of O'Farell (5).
  • Another advantageous group of peptides, polypeptides and proteins of the invention is constituted by those of amino acid composition defined in Table I, which represent inhibitors of the proliferation of osteoblasts and which exhibit a molecular weight of about 27 kD measured by one- dimensional SDS-PAGE electrophoresis, an isoelectric point of about 4.0 to 5.5, measured by two-dimensional SDS-PAGE electrophoresis according to the technique of O'Farrell.
  • Another subject of the invention is any peptide or polypeptide contained in one of the following polypeptide sequences: S1, S2, S3, S1S2, S1S3, S3S1, S2S1, S2S3, S1S2S3, S1S3S2, S2S1S3, S2S3S1, S3S1S2 or S3S2S1, exhibiting properties of inhibition of the proliferation of osteoblasts.
  • the free reactive functions which are present in certain of the amino acids which form part of the constitution of the chain sequence of the peptides, polypeptides and proteins of the invention in particular the free carboxyl groups which are borne by the glutamine groups or by the C- terminal amino acid, on the one hand, and/or the free groups borne by the N-terminal amino acid, or by an amino acid in the interior of the peptide chain, for example lysine, on the other, may be modified to the extent that this modification does not impair the properties of inhibition of the growth of osteoblasts of the peptides, polypeptides and proteins of the invention.
  • the carboxyl groups mentioned above may be acylated or esterified.
  • the amine or ester functions or the two terminal amino acids may themselves be implicated in linkage with other amino acids.
  • the N-terminal amino acid may be linked to a sequence comprising from one to several amino acids corresponding to a part of the C-terminal region of another peptide.
  • any peptide sequence resulting from the modification by substitution and/or by addition and/or by suppression of one or several amino acids of the peptides, polypeptides and proteins according to the invention form part of the invention to the extent that this modification does not impair the properties of the polypeptides and proteins mentioned.
  • the polypeptides and proteins according to the invention may or may not be glycosylated, particularly in certain of their sites of glycosylation of the type Asn-X-Ser or Asn-X-Thr, X representing any amino acid.
  • Another subject of the invention is one of the peptide sequences S1, S2 or S3 defined previously.
  • Another subject of the invention is an inhibitory protein of the proliferation of osteoblasts likely to be obtained by the following steps:
  • Another subject of the invention is the protein defined above purified by HPLC, for example after trypsinization.
  • the invention also relates to the nucleic acids coding for the peptides, polypeptides and proteins defined above.
  • the invention also relates to a procedure for the preparation of a peptide, polypeptide or protein according to the invention comprising the following steps:
  • polypeptides and proteins of the invention may be prepared according to standard techniques in the field of peptide synthesis.
  • the synthesis may be carried out in homogeneous solution or on a solid phase.
  • polypeptides and proteins of the invention may also be prepared according to the method described by R.D. Merrifield in the article entitled “Peptide synthesis on a solid phase” (J. Am. Chem. Soc, 45, 2149-2154).
  • the invention also relates to the antibodies produced starting from the peptides, polypeptides or proteins of the invention and obtained by immunization of an animal with the aid of a polypeptide or a protein of the invention. It is obvious that this production is not limited to polyclonal antibodies.
  • any monoclonal antibody produced by any hybridoma likely to be formed according to standard methods starting from spleen cells of an animal, in particular a mouse or a rat, immunized against a purified peptide or a purified polypeptide or a purified protein of the invention, on the one hand, and cells of a myeloma line, on the other, and selected for its ability to produce the monoclonal antibodies recognizing the peptides, polypeptides or proteins utilized initially for the immunization of the animal.
  • the invention also relates to any antibody of the invention labelled by a suitable marker of the enzymatic, fluorescent, chemiluminescent or radioactive type.
  • the invention relates to a diagnostic procedure, in particular for detection, identification and quantitation in vitro of antibodies directed against one of the proteins or one of the polypeptides or peptides of the invention and correlatable with a disease, these antibodies being present in a biological sample containing them, this procedure comprising:
  • the biological medium is constituted by serum.
  • the detection may be carried out by any standard procedure.
  • a preferred method makes use of an immuno-enzymatic procedure according to a ELISA or immunofluorescent or radio-immunological RIA or equivalent technique.
  • the invention also relates to a diagnostic procedure, in particular of detection, identification and quantitation in vitro of a protein, a polypeptide or a peptide of the invention in a human biological sample likely to contain them, this procedure comprising:
  • the biological medium is constituted by human serum.
  • kit comprising:
  • the said reagents making it possible to detect the antigen/antibody complexes which have been produced by the immunological reaction, the said reagents possibly having a marker or being capable of being known by a labelled reagent, more particularly in the case in which the antibody mentioned above is not labelled.
  • kits comprising: - a peptide, a polypeptide of protein of the invention,
  • the said reagents making it possible to detect the antigen/antibody complexes which have been produced by the immunological reaction, the said reagents possibly having a marker or being capable of being recognized by a labelled reagent, more particularly in the case in which the above polypeptide or protein is not labelled.
  • the invention also relates to a pharmaceutical composition containing a polypeptide or protein of the invention in combination with a pharmaceutically acceptable vehicle.
  • Figure 1 corresponds to the standard profile obtained after hydroxyapatite chromatography eluted at 1 ml/min in a solution of 10 mM of phosphate.
  • the profile obtained shows a peak at 10 mM of phosphate buffer, a peak at 50 mM of phosphate buffer and several peaks obtained with the gradient (from 50 to 250 mMPi) of phosphate buffer.
  • a protein is eluted at 200 mM of phosphate buffer: it is the "BMP" protein, already mentioned above (1) and pinpointed by the arrow bearing the mention "osteo-inducing fraction".
  • Figure 2 depicts the chromatography device of the invention.
  • Figure 2a represents the chromatography device in its entirety;
  • Figure 2b represents a breakdown of the lower part of the column and of the supporting device and
  • Figure 2c represents a bottom view of the reference 16, the significance of which will be given later.
  • Figure 2a is shown in 1 the upper reservoir intended to receive the eluant and fitted with means to supply the buffer continuously such as a pipette 4 conveying the buffer through the intermediary of a pump.
  • the buffer overflow runs off through the means of evacuation such as the small cylinder 3.
  • In 2 is represented the negative electrode (which may be constituted by a platinum wire).
  • In 6, is represented the column, in the interior of which the gel is located.
  • the upper outlet of the column is in contact with the upper reservoir, for example through the intermediary of a joint 5 located beneath the reservoir 1.
  • In 7 is represented the elution chamber receiving the column and in 8 a conduit, such as a capillary, connected to the fraction collector via a pump and in 9 the lower reservoir into which the column is immersed.
  • a conduit such as a capillary
  • Figure 2b is represented in 6 the lower end of the column, in 11 the first porous disk of plastic, in 12 the collar determining the volume of the elution chamber, in 13 the collar of larger diameter than that of the elution chamber and which accommodates all of the upper part of the device, including the column, the lower end of the column fitting into this collar.
  • In 14 is represented the Amicon PM10 membrane pierced at its center by a capillary connected in the elution chamber to the collector.
  • a third disk of plexiglass in which the Amicon membrane and the second disk of plastic are maintained, for example, by screws and accommodate all of the upper part of the device, including the column, and the disposition of the means of fastening, for example the screws of which defines a ring.
  • the third disk 16 seals the base of the column.
  • Figure 3 shows the profile obtained after chromatography on the preparative column.
  • the first peaks correspond to the proteins of low molecular weight, i.e. lower than about 20 kD. Hence, it is necessary to wait for the tenth fraction in order to detect the protein of about 27 kD of the invention.
  • Figure 4a represents a SDS-PAGE of fractions collected immediately from the preparative column.
  • the fractions analysed correspond to those containing an individual protein and are located by following the profile of the chromatogram.
  • Two of these analysed fractions contain the protein of 27 kD of the invention.
  • the first line corresponds to a bovine albumin control, the second to the molecular weight standard, the third to the starting material, that is the non- collagenous protein insoluble in Triton X-100.
  • the next four lines correspond to individual proteins, each one corresponding to a peak on the profile of the chromatogram.
  • the lines 9 and 10 correspond to the protein of 27 kD of the invention.
  • the analysis is carried out on a discontinuous gel in the presence of SDS with a gel of concentration of 0.3% of A-AA (acrylamide- bisacrylamide) and a resolution gel of 12.6% of A-AA.
  • a current of about 150 V and of 15 mA is applied when the proteins pass through the concentration gel (i.e. during about 2 h) in order to be subsequently increased to about 200 V and 25 mA, when the proteins pass through the resolution gel i.e. during about 4 hours.
  • the protein bands are visualized by staining with silver nitrate.
  • the standard which contains different markers including phosphorylase at 94,400 daltons, bovine serum albumin at 67,000 daltons, ovalbumin at 43 , 000 daltons , carbonic anhydrase at 30,000 daltons, the soya trypsin inhibitor at 20,100 daltons and ribonuclease at 14,400 daltons.
  • Figure 4b shows the result of a SDS-PAGE carried out on the protein of the invention at variable concentrations in the presence or not of reducing agent at variable concentrations in order to determine the influence of reduction on the protein of the invention.
  • the first line corresponds to the starting material (non-collagenous proteins insoluble in Triton X-100), the second line to the molecular weight standard, the third line to the protein of the invention of 27 kD in the presence of mercaptoethanol, the fourth line to the protein of the invention without reducing agent, the fifth line to the protein of the invention in the presence or mercaptoethanol two times less concentrated, the sixth line to the protein of the invention without reducing agent and two times less concentrated, the seventh line to the molecular weight standard.
  • the bands are revealed by staining with silver nitrate.
  • Figure 5 corresponds to a gel in two dimensions stained with silver nitrate.
  • the molecular weight standard is the same as that utilized for the one- dimensional gel.
  • the first dimension relates to the isoelectric point. It is a matter of the standard method in the presence of servalites (Serva, W-Germany) which form a pH gradient from 3.5 to 7, reducing agent (mercaptoethanol, Biorad) and a dissociating agent, that is 9.5 M urea (Sigma). It is possible to distinguish on this gel a long band which corresponds to the protein of the invention and a very short band which corresponds to an impurity.
  • servalites Serva, W-Germany
  • reducing agent mercaptoethanol, Biorad
  • a dissociating agent that is 9.5 M urea (Sigma). It is possible to distinguish on this gel a long band which corresponds to the protein of the invention and a very short band which corresponds to an impurity.
  • the biological assays were carried out with the protein of the invention obtained after the preparative chromatography and the results obtained show that this impurity does not modify the biological properties of the protein of the invention. It may be deduced from this that the procedure of the invention makes it possible to obtain a protein in a satisfactory state of purity.
  • HPLC analysis of the protein of the invention was carried out on the protein free from the impurity detected on two-dimensional SDS-PAGE.
  • One star (*) signifies that p is less than 0.05
  • two stars (**) signify that p is less than 0.01
  • three stars (***) signify that p is less than 0.005
  • four stars (****) signify that p is less than 0.001.
  • the statistical significance results from using the Mann and Whitney test.
  • control corresponds to the blank column and the incorporation of the protein of the invention corresponds to the hatched columns.
  • the inhibition is statistically significant.
  • Figure 7 shows an inhibitory activity of the protein of 27 kD on the proliferation of ROS 17/2.8 cells for doses of 10 ⁇ g/ml (column with the widely spaced hatchings), 1 ⁇ g/ml (column with the closely spaced hatchings), 0.1 ⁇ g/ml (column with the dots) in comparison with identical doses containing:
  • the control is constituted by BSA.
  • "NS" signifies that the result is not significant; ** correspond to p ⁇ 0.01; *** correspond to p ⁇ 0.005 and **** correspond to p ⁇ 0.001.
  • the values represent the mean ⁇ SD.
  • the column with widely spaced hatchings corresponds to a dose of 3.5 ⁇ g/ml, that with closely spaced hatchings to a dose of 0.35 ⁇ g/ml and that with dots to a dose of 0.035 ⁇ g/ml.
  • the measurement of the inhibition of the proliferation of the ROS 17/2.8 cells is represented in counts per minute (cpm) corresponding to the detection of tritiated thymidine.
  • the inhibition is significant for the protein of the invention at doses lower than those used for known inhibitors.
  • the pulverized material is demineralized for 72 hours in a solution of 0.6 N HCl (Ferak) at 4oC.
  • the filtered solution is concentrated with the aid of a Amicon cell of 200 cc (Amicon division, Ultrafiltration Cell, USA) fitted with a Diaflo membrane (MW 10, Diaflo Ultrafilters, Amicon division, USA).
  • the final volume represents about one tenth of the starting solution.
  • the concentrated solution is then dialysed against distilled water (dH 2 O), in the cold room. Dialysis membranes with a retaining power of 6 - 8 kD (Spectra- Por, USA) are used. The water is changed 3 times per day during 3 days.
  • the content of the dialysis membrane is brought to 35°C, it is centrifuged at 9000 rpm for 30 minutes at 30-35°C. The supernatant is discarded and the precipitate is washed abundantly with dH 2 O so as to remove all traces of citric acid.
  • the precipitate is resolubilized in about 2 L of chloroform/methanol 1/1 (Ferak), at room temperature overnight on a magnetic stirrer. In this way the lipids and the lipoproteins are removed.
  • the dialysis in distilled water in the cold room takes about 72 hours.
  • the content of the dialysis membrane is then centrifuged at 9000 rpm at 48oC, for 30 minutes, the precipitate is lyophilized, it is a matter of the non-collagenous proteins insoluble in the Triton X-100 (that is 2.5 g).
  • the supernatant, soluble in Triton X-100 and in distilled water, represents mainly the proteins of 6, 24, 34 kD (that is 6 g).
  • HAP is selected as means of purification, given the high affinity which the non-collagenous proteins show for this substrate.
  • 1 gr of HAP Bio-Gel HTP, BioRad
  • 40 g of HAP are utilized in order to absorb 400 mg of non- collagenous proteins.
  • a chromatography column (Pharmacia) of a volume of about 200 cm 3 is used, however its volume is reduced to about 160 cm 3 with the aid of a piston, given that 40 gr of HAP only occupy 140 cm 3 .
  • the HAP is immersed in the buffer 0 and may never become dry, all of the chromatography takes place at room temperature.
  • the buffer 0 requires:
  • the buffer 0 has the following composition: 6 M urea + 0.01 M of phosphate (600 ml stock sol. of urea + 10 ml stock sol. of phosphate + 390 ml dH 2 O for 1 L of buffer).
  • the HAP is washed with the buffer 0 by shaking gently by hand. It is allowed to settle for one hour, the supernatant is then discarded, the HAP is rewashed with the buffer 0 for a half hour by operating in the same manner. After this, the supernatant is discarded and replaced by fresh buffer 0, the HAP is shaken more vigorously and poured into the column in one movement. In this case, a short and wide column is preferred to a long and narrow column in contrast to the columns intended for chromatographies by gel filtration (cf. a Sephadex S-200).
  • the column After 24 hours, the column is placed in closed circuit and washed with the buffer 0, its flow rate is thus identical to what will be the rate of elution of the chromatography, that is 1 ml/min, this being defined because of a pump, the speed of rotation of which is adjustable.
  • the 400 mg of non- collagenous proteins are dissolved in 40 ml of buffer 0 in a Erlenmeyer on a magnetic plate at 37oC during the same period of time. They are then centrifuged at 20,000 rpm, 15 min. The supernatant is chromatographed.
  • the lower end of the column is connected to a U.V. detector (reading at 280 nm, LKB, Sweden), itself connected to a graphic recorder (LKB):
  • the chromatography takes place under the following conditions:
  • a fraction is recovered at 10 mM of phosphate buffer, another fraction at 50 mM of phosphate buffer and in the gradient of phosphate buffer a fraction is recovered which emerges at 200 mM of phosphate buffer (and which contains the BMP protein).
  • the fraction emerging at 10 mM of phosphate buffer is recovered when a peak is observed, obtained when about 3 times the volume of the column of HAP (that is 420 cc) of buffer 0 have passed through, and the fraction collected is dialysed in water, then lyophilized.
  • the HAP chromatography made it possible to obtain a fraction emerging at 10 mM of phosphate buffer, which fraction contains a set of proteins of molecular weight of about 15 , 000 to about 40 , 000 daltons, and contains in particular the sought protein,
  • This instrument made of plexiglass consists mainly of an upper reservoir, sides 12 cm/12 cm square and 9 cm high, comprising a negative electrode (platinum wire), a cylindrical point making it possible to maintain a constant level in the reservoir and a central outlet equipped for example with a thread on which a column 4 cm in diameter and 18 cm high is connected.
  • the lower end of the column comes to fit partially into a second wider cylinder about 3 cm high at the bottom of which a collar 0.5 cm high defines the volume of the elution chamber.
  • a disk of porous plastic is placed between the base of the column, in direct contact with the acrylamide gel, and the internal collar.
  • a Amicon membrane (Diaflo, MW 10, Amicon Corp., USA) covers a second porous disk, itself placed on a disk of plexiglass with spokes allowing the passage of current and which seals the base of the column, for example by means of screws.
  • the disks contiguous to the membrane and the membrane are pierced at their center with a small hole allowing the passage of a capillary connecting the elution chamber to the fraction collector via a pump (LKB).
  • LLB pump
  • the base of the column with the elution chamber is immersed in a reservoir of dimensions preferably identical to those of the upper reservoir which contains a positive electrode (platinum wire) as well as the same buffer.
  • the volumes of the reservoirs are maintained constant by the flow from the upper reservoir into the lower which is emptied as a function of the speed of rotation of the pump (with 4 channels) which pumps the proteins in the buffer of the elution chamber towards the collector while replenishing the upper reservoir at the same rate.
  • the buffer used is the same as that intended for the electrophoreses: 0.04 M of Tris (Ferak) + 0.1% of SDS (BioRad) + 0.384 M of glycine (Ferak) in distilled water at pH 8.3 (Tris-HCl).
  • the column is composed of a 3% concentration gel of acrylamide-bisacrylamide (A-AA BioRad) which occupies 15% of the volume of the column, which rests on a resolution gel of 12% A-AA which occupies 30% of the column which itself is superposed on a second resolution gel of 17% A-AA and which also occupies 30% of the column.
  • A-AA BioRad acrylamide-bisacrylamide
  • the conditions of chromatography are the following: the electrodes are connected to a current generator (Consort E 554) which delivers 70 mA, the pump which turns at 0.5 ml/min connects the elution chamber to the U.V. detector (reading at 180 nm) linked to a graphic recorder (the paper speed which is 3 cm/hr and the impedance of which is 10 mV) and to the fraction collector which collects 3 ml/tube every 6 minutes.
  • the purification which takes place at room temperature, lasts about 72 hours.
  • This protein obtained and purified to an essentially homogeneous state starting from bovine bone according to the procedure of the invention has an apparent molecular weight of 27,000 daltons and an isoelectric point (Fig. 5) of about 4.0 to about 5.5 according to the technique of O'Farrell (5).
  • the immediate electrophoresis on the fractions collected after the preparative column makes it possible to group the fractions containing only the protein of 27 kD, to concentrate them in a Amicon cell (Amicon Ultrafiltration Cell, M-52, Amicon Corp., USA) equipped with a filtration membrane (Diaflo, PM 10, Amicon Corp., USA) so as to have no more than very small volumes to dialyse.
  • Amicon cell Amicon Ultrafiltration Cell, M-52, Amicon Corp., USA
  • a filtration membrane Diaflo, PM 10, Amicon Corp., USA
  • the content of the dialysis membranes (precipitate and supernatant) are frozen, then lyophilized. They are resolubilized in 6 M GuHCl (Aldrich-Chemie, W-Germany), and redialysed in distilled water in the cold room for a further 3 days at least. After being freed from GuHCl and salts of SDS, both of which are denaturants, during the second dialysis, proteins are obtained which have recovered their biological activity.
  • the protein of 27 kD is trypsinized, the separated on High Pressure Liquid Chromatography (HPLC).
  • HPLC High Pressure Liquid Chromatography
  • the sequence of amino acids is carried out on the major peaks thus obtained with the aid of a sequence analyser (Beckman 121) according to the standard method.
  • a first subunit, S1 corresponds to:
  • the second subunit, S2 corresponds to:
  • the third subunit, S3 is composed of:
  • values represent approximately the number of residues of the amino acids indicated per mole of respective proteins (subunits), the molecular weight of which is estimated by the method conventionally used such as a SDS-PAGE.
  • the values for these protein subunits of the invention include the experimental error of the type of analysis of the composition of the amino acids; ND or "not determined” signifies there was no determination for the amino acids indicated.
  • PBS phosphate buffer
  • This medium is mainly composed of: modified Eagle medium (MEM, Gibco), enriched with 10% of heat- inactivated FCS (Gibco), 1% of L-Glu (Gibco), 100 U/ml of penicillin (Gibco), 100 ⁇ g/ml of streptomycin (Gibco) and 1% of non-essential amino acids (NEAA, Gibco).
  • the cells are stored in an incubator at 37oC and 5% CO 2 . A single layer of cells entirely covers the interior of the Petri dish after 4 to 5 weeks. There are then about 2 times 10 6 cells per dish.
  • the cells at confluence are trypsinized (Trypsin solution/EDTA, Gibco) in the following manner:
  • the dishes are rinsed several times in a little medium so as to obtain a final volume of about 10 ml after several rinsings.
  • the cells are transferred to Falcon culture dishes with 24 wells at a density of 10 4 cells/cm 2 containing the medium + 0.1% of BSA (Sigma, USA) or 2% of FCS passed over charcoal so as to have a medium depleted in serum and growth factors. It is a question of the first "subculture”.
  • the inhibitory protein of the invention are tested for 72 hours on 10 4 cells/cm 2 and their proliferation is measured by the incorporation of tritiated thymidine ( 3 H-TdR, Amersham, U.K.) into the DNA, added to the culture during the last 20 hours. After this, the medium is aspirated and the cells are washed in 500 ⁇ l of 10% trichloroacetic acid (TCA, Sigma) on crushed ice. This operation is repeated twice for 10 minutes. A last washing, not on ice, is done in 500 ⁇ l of ethanol/ether 3:1 (Ferak). The dishes are dried.
  • tritiated thymidine 3 H-TdR, Amersham, U.K.
  • alkaline phosphatase The synthesis of alkaline phosphatase by the osteoblast cells obtained from the long bones of the rat is assayed in order to confirm their phenotypic character (CBR, Boehringer Diagnostica, W-Germany). This enzyme is a specific marker for osteoblasts and reveals the homogeneity of the culture.
  • an inhibitory activity is observed in vitro with regard to a healthy osteoblast cell line but also in the case of osteoblasts of a malignant cell line derived from rat osteosarcoma (ROS 17/2.8).
  • the protein of the invention is different from the inhibitor of 38 kD ( Figure 7) by its sequence, given that it was confirmed that this inhibitor of 38 kD shares an entire sequence homology with osteonectin (2).
  • the doses of the protein of the invention to be administered depend on the in vitro or in vivo model selected, on the target cells and/or influential external circumstances such as certain diseases of the bone like Paget's disease or the developmental stage of a bone tumor, for example.
  • Each active preparation may include a judicious bioactive material such as growth factors, chemotactic agents, steroids, antibiotics, anti-inflammatory agents and other similar substances.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à un procédé qui permet d'obtenir une protéine purifiée jusqu'à un état homogène satisfaisant, en partant d'un extrait de protéines non collagènes de matrice osseuse, ainsi qu'à un dispositif de réalisation de ce procédé, à une protéine inhibant la prolifération des ostéoblastes, qui est susceptible d'être obtenue par ledit procédé. Ce procédé consiste: à soumettre l'extrait de protéines non collagènes, préalablement solubilisé dans un solvant, à une chromatographie préparatoire dans la phase liquide d'une colonne de gel à l'aide d'un tampon d'élution et d'un champ électrique, dans des conditions propres à produire l'élution de la protéine désirée, qu'on trouve, pendant ou à la fin de la chromatographie présente en solution dans le tampon d'élution, seule et sans contaminants, dans au moins l'une des fractions recueillies à la sortie de la colonne, à récupérer la fraction contenant la protéine désirée en solution dans le tampon d'élution; à retirer le tampon d'élution et à récupérer la protéine désirée, laquelle est soumise, si nécessaire, à une étape de remise à l'état naturel et/ou à une étape de réactivation.
PCT/EP1990/002295 1989-12-20 1990-12-20 Nouveau procede permettant d'obtenir des proteines en partant d'un extrait de proteines non collagenes provenant de tissu osseux et utilisation de ce procede pour la preparation d'une nouvelle proteine inhibant la proliferation des osteoblastes WO1991008749A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP89403592 1989-12-20
EP89403592.2 1989-12-20

Publications (1)

Publication Number Publication Date
WO1991008749A1 true WO1991008749A1 (fr) 1991-06-27

Family

ID=8203017

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1990/002295 WO1991008749A1 (fr) 1989-12-20 1990-12-20 Nouveau procede permettant d'obtenir des proteines en partant d'un extrait de proteines non collagenes provenant de tissu osseux et utilisation de ce procede pour la preparation d'une nouvelle proteine inhibant la proliferation des osteoblastes

Country Status (2)

Country Link
AU (1) AU7066091A (fr)
WO (1) WO1991008749A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019132418A1 (fr) * 2017-12-27 2019-07-04 ㈜셀트리온 Procédé de diafiltration
CN117129366A (zh) * 2023-10-25 2023-11-28 武汉大学 一种蛋白质提取液中高分子量蛋白质提取率的测试方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2722175A1 (de) * 1976-05-18 1977-12-01 Willem Gerrit Roskam Anlage zur preparativen elektrophorese
EP0271668A1 (fr) * 1986-10-22 1988-06-22 Gesellschaft für Biotechnologische Forschung mbH (GBF) Matière stimulant la croissance, procédé de fabrication et composition thérapeutique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2722175A1 (de) * 1976-05-18 1977-12-01 Willem Gerrit Roskam Anlage zur preparativen elektrophorese
EP0271668A1 (fr) * 1986-10-22 1988-06-22 Gesellschaft für Biotechnologische Forschung mbH (GBF) Matière stimulant la croissance, procédé de fabrication et composition thérapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biological Abstracts, vol. 88, no. 2, 15 July 1989 (Philadelphia, PA;US) C.D. Evans et al.: "Does myeloma secrete an osteoblast inhibiting factor?" *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019132418A1 (fr) * 2017-12-27 2019-07-04 ㈜셀트리온 Procédé de diafiltration
KR20190079530A (ko) * 2017-12-27 2019-07-05 (주)셀트리온 투석 여과 방법
KR102754228B1 (ko) * 2017-12-27 2025-01-14 (주)셀트리온 투석 여과 방법
CN117129366A (zh) * 2023-10-25 2023-11-28 武汉大学 一种蛋白质提取液中高分子量蛋白质提取率的测试方法
CN117129366B (zh) * 2023-10-25 2024-01-16 武汉大学 一种蛋白质提取液中高分子量蛋白质提取率的测试方法

Also Published As

Publication number Publication date
AU7066091A (en) 1991-07-18

Similar Documents

Publication Publication Date Title
EP0148155B1 (fr) Facteurs ostéogéniques
US4804744A (en) Osteogenic factors
US5290763A (en) Osteoinductive protein mixtures and purification processes
Urist et al. Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography.
US4761471A (en) Bone morphogenetic protein composition
US4789732A (en) Bone morphogenetic protein composition
US4619989A (en) Bone morphogenetic protein composition
Dimuzio et al. Phosphophoryns—major noncollagenous proteins of rat incisor dentin
Urist et al. Human bone morphogenetic protein (hBMP)
Trelstad et al. Isolation of two distinct collagens from chick cartilage
Seyedin et al. Purification and characterization of two cartilage-inducing factors from bovine demineralized bone.
Liem et al. Intermediate filaments in nervous tissues
US4795804A (en) Bone morphogenetic agents
JP3209740B2 (ja) 骨形成因子
RU1802814C (ru) Способ очистки пептидилглициновой @ -амидирующей монооксигеназы и способ получени @ -амидированного пептида
Shimizu et al. Proteolytic enzyme in porcine immature enamel
JPS62501701A (ja) 均質なエリトロポエチン
EP0563329A1 (fr) Peptides angiogeniques
Veis et al. Isolation and characterization of the cyanogen bromide peptides from the α1 and α2 chains of acid-soluble bovine skin collagen
Rosenstreich et al. A human urine-derived interleukin 1 inhibitor. Homology with deoxyribonuclease I.
Volpin et al. Differences between CNBr peptides of soluble and insoluble bovine collagens
JPH08509960A (ja) 骨原性成長オリゴペプチドおよびそれを含む医薬組成物
WO1991008749A1 (fr) Nouveau procede permettant d'obtenir des proteines en partant d'un extrait de proteines non collagenes provenant de tissu osseux et utilisation de ce procede pour la preparation d'une nouvelle proteine inhibant la proliferation des osteoblastes
US4935497A (en) Dentin chondrogenic inductive agent
Dhawan et al. A novel peptide from amyloid P component supports cell attachment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA HU JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA